Evidence map›Paper›PMID 41243213›Full record

Trial reportBrain : a journal of neurology2025

Boosting hemianopia recovery: the power of interareal cross-frequency brain stimulation.

Estelle Raffin, Michele Bevilacqua, Fabienne Windel, Pauline Menoud, Roberto F Salamanca-Giron, Sarah Feroldi, Sarah B Zandvliet, Nicola Ramdass, Laurijn Draaisma, Patrik Vuilleumier and 6 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Brain : a journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Estelle RaffinDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva 1202, Switzerland.ORCID 0000-0003-3262-5251
Michele BevilacquaDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva 1202, Switzerland.ORCID 0000-0001-5647-2822
Fabienne WindelDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva 1202, Switzerland.
Pauline MenoudDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva 1202, Switzerland.
Roberto F Salamanca-GironDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva 1202, Switzerland.
Sarah FeroldiDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva 1202, Switzerland.
Sarah B ZandvlietDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva 1202, Switzerland.
Nicola RamdassDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva 1202, Switzerland.
Laurijn DraaismaDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva 1202, Switzerland.
Patrik VuilleumierLaboratory of Neurology and Imaging of Cognition, Department of Fundamental Neurosciences, University Geneva, Geneva 1205, Switzerland.ORCID 0000-0002-8198-9214
Adrian G GuggisbergDepartment of Clinical Neuroscience, University Hospital of Geneva Medical School, Geneva 1201, Switzerland.
Christophe BonvinStroke Unit Valais, Hôpital du Valais, Sion 1951, Switzerland.
Lisa FleuryDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva 1202, Switzerland.
Krystel R HuxlinThe Flaum Eye Institute and Center for Visual Science, University of Rochester, Rochester, NY 14620, USA.ORCID 0000-0001-7138-6156
Elena BeanatoDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva 1202, Switzerland.
Friedhelm C HummelDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva 1202, Switzerland.ORCID 0000-0002-4746-4633

Funding

Bertarelli Foundation BC77O7Defitech FoundationNational Science Foundation PR00P3_179867
6 · The paper itself

Abstract

Visual field loss is a common consequence of stroke and manifests in approximatively one-third of patients in the chronic stage. Such loss can significantly impact daily life activities, compromising tasks such as reading, navigating or driving. Although slow and labour intensive, evidence suggests that early interventions with tailored rehabilitation programmes might stimulate visual recovery and improve quality of life in stroke survivors. To enhance the effects of such rehabilitation programmes, we designed a novel, non-invasive, pathway-specific, physiology-inspired cross-frequency brain stimulation protocol, where complex oscillatory signal integration was inferred from phase-amplitude coupling of oscillatory signals between the primary visual cortex and the motion-sensitive medio-temporal area. Sixteen stroke patients were enrolled in a double-blind, randomized, cross-over trial, during which they performed two blocks of 10 daily training sessions of a direction discrimination task, combined with one of the two cross-frequency transcranial alternative brain stimulation (cf-tACS versus control cf-tACS) conditions. We found that the cf-tACS condition promoting feedforward visual inputs to the medio-temporal area significantly enhanced motion discrimination performance and shifted visual field borders (i.e. through localized enlargement of isopters). Behavioural improvements associated with a change in oscillatory activity within motion processing pathways were proportional to the amount of residual structural fibres along these pathways and perilesional primary visual cortex activity. In sum, we report, for the first time, that cf-tACS, a novel, pathway-specific, physiology-inspired brain stimulation approach, is able to boost the efficacy of perceptual training, restoring visual motion processing and reducing the severity of visual impairments in adult stroke patients.

Indexed as

HemianopsiaRecovery of FunctionStroke RehabilitationTranscranial Direct Current StimulationAdultAgedCross-Over StudiesDouble-Blind MethodFemaleHumansMaleMiddle AgedMotion PerceptionStrokeVisual Fieldsbifocal transcranial alternating current stimulationcross-frequency interactionsinterareal synchronizationmotion direction discriminationvisual recovery

Identifiers

PMID41243213
PMCPMC12677025

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.